High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy-Reference-Cited by-同舟云学术

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

Published:2018-01-08 Issue:2 Volume:24 Page:144-153
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Krieg Carsten^ORCID,Nowicka Malgorzata,Guglietta Silvia,Schindler Sabrina,Hartmann Felix J^ORCID,Weber Lukas M^ORCID,Dummer Reinhard,Robinson Mark D^ORCID,Levesque Mitchell P^ORCID,Becher Burkhard^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4466.pdf

Reference49 articles.

1. Topalian, S.L., Drake, C.G. & Pardoll, D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity. Curr. Opin. Immunol. 24, 207–212 (2012).

2. Topalian, S.L. et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).

3. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014).

4. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).

5. Motzer, R.J. et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).

Cited by 583 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining intra-tumoral and systemic immune biomarkers for locally advanced head-and-neck cancer – detailed protocol of a prospective, observatory multicenter trial (ImmunBioKHT) and first results of the immunophenotyping of the patients’ peripheral blood;Frontiers in Oncology;2024-09-13

2. Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist’s Perspective on Current Knowledge;International Journal of Molecular Sciences;2024-08-31

3. Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancer;2024-08-28

4. Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data;Signal Transduction and Targeted Therapy;2024-08-26

5. SERS surgical navigation with postsurgical immunotherapy of local microtumors and distant metastases for improved anticancer outcomes;Science Advances;2024-08-16